1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 1,267 results.

HL - 452

Safety and Efficacy of ABVD protocol in Pregnant Patients with Classic Hodgkin Lymphoma: A single center experience

Shaimaa El-Ashwah

Poster Presenter: Shaimaa El-Ashwah

$Thumbnail for Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review$

MM - 453

Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Mahboob Younus Shaik

Poster Presenter: Mahboob Younus Shaik

SOHO 2026 Annual Meeting

Topics

Safety and Efficacy of ABVD protocol in Pregnant Patients with Classic Hodgkin Lymphoma: A single center experience

Durability of Response, Mechanisms of Resistance, and Retreatment Outcomes Following CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Review

Persistent DNMT3A Mutations Predicting Relapse After Acute Myeloid Leukemia Remission: A Systematic Review of Molecular Persistence and Circulating DNA Dynamics

Rising Terminal Nutritional-Frailty Vulnerability Despite Declining Overall Multiple Myeloma Mortality: National Trends, Co-Occurring Vulnerability Markers, Place-of-Death Patterns, and Disparities in the United States

Improving Survival and Increasing Disease Burden in Chronic Myelomonocytic Leukemia: Population-Based Trends and Projections From SEER, 2000-2022

Artificial Intelligence in Chronic Myeloid Leukemia: Assessing the Accuracy and Clinical Utility of Large Language Models

Secondary Primary Malignancies Associated With BCMA-Directed Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A FAERS Pharmacovigilance Analysis

Did Novel Agents Change the Curve? Survival Acceleration in Hodgkin Lymphoma After 2016: SEER Analysis

Long-term follow-up of Oral Decitabine/Cedazuridine (ASTX727) Plus Venetoclax in Older or Unfit patients with Newly Diagnosed Acute Myeloid Leukemia